145 related articles for article (PubMed ID: 9306428)
1. NCI's anticancer drug screening program may not be selecting for clinically active compounds.
Brown JM
Oncol Res; 1997; 9(5):213-5. PubMed ID: 9306428
[TBL] [Abstract][Full Text] [Related]
2. Identification of non-cross-resistant platinum compounds with novel cytotoxicity profiles using the NCI anticancer drug screen and clustered image map visualizations.
Fojo T; Farrell N; Ortuzar W; Tanimura H; Weinstein J; Myers TG
Crit Rev Oncol Hematol; 2005 Jan; 53(1):25-34. PubMed ID: 15607933
[TBL] [Abstract][Full Text] [Related]
3. The primary in vitro anticancer activity of "half-mustard type" phenothiazines in NCI's revised anticancer screening paradigm.
Wuonola MA; Palfreyman MG; Motohashi N; Kawase M; Gabay S; Gupta RR; Molnár J
Anticancer Res; 1998; 18(1A):337-48. PubMed ID: 9568100
[TBL] [Abstract][Full Text] [Related]
4. Molecular modes of action of cephalotaxine and homoharringtonine from the coniferous tree Cephalotaxus hainanensis in human tumor cell lines.
Efferth T; Sauerbrey A; Halatsch ME; Ross DD; Gebhart E
Naunyn Schmiedebergs Arch Pharmacol; 2003 Jan; 367(1):56-67. PubMed ID: 12616342
[TBL] [Abstract][Full Text] [Related]
5. Semisynthesis and in vitro anticancer activities of andrographolide analogues.
Jada SR; Subur GS; Matthews C; Hamzah AS; Lajis NH; Saad MS; Stevens MF; Stanslas J
Phytochemistry; 2007 Mar; 68(6):904-12. PubMed ID: 17234223
[TBL] [Abstract][Full Text] [Related]
6. SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 1: cellular pharmacology, in vitro and initial in vivo antitumor activity.
Hartley JA; Spanswick VJ; Brooks N; Clingen PH; McHugh PJ; Hochhauser D; Pedley RB; Kelland LR; Alley MC; Schultz R; Hollingshead MG; Schweikart KM; Tomaszewski JE; Sausville EA; Gregson SJ; Howard PW; Thurston DE
Cancer Res; 2004 Sep; 64(18):6693-9. PubMed ID: 15374986
[TBL] [Abstract][Full Text] [Related]
7. Benzethonium chloride: a novel anticancer agent identified by using a cell-based small-molecule screen.
Yip KW; Mao X; Au PY; Hedley DW; Chow S; Dalili S; Mocanu JD; Bastianutto C; Schimmer A; Liu FF
Clin Cancer Res; 2006 Sep; 12(18):5557-69. PubMed ID: 17000693
[TBL] [Abstract][Full Text] [Related]
8. Data mining the NCI cancer cell line compound GI(50) values: identifying quinone subtypes effective against melanoma and leukemia cell classes.
Marx KA; O'Neil P; Hoffman P; Ujwal ML
J Chem Inf Comput Sci; 2003; 43(5):1652-67. PubMed ID: 14502500
[TBL] [Abstract][Full Text] [Related]
9. Characterization of anticancer agents by their growth inhibitory activity and relationships to mechanism of action and structure.
Keskin O; Bahar I; Jernigan RL; Beutler JA; Shoemaker RH; Sausville EA; Covell DG
Anticancer Drug Des; 2000 Apr; 15(2):79-98. PubMed ID: 10901296
[TBL] [Abstract][Full Text] [Related]
10. The hollow fiber assay: continued characterization with novel approaches.
Hall LA; Krauthauser CM; Wexler RS; Hollingshead MG; Slee AM; Kerr JS
Anticancer Res; 2000; 20(2A):903-11. PubMed ID: 10810375
[TBL] [Abstract][Full Text] [Related]
11. Screening for and identification of novel agents directed at renal cell carcinoma.
Mertins SD; Myers TG; Hollingshead M; Dykes D; Bodde E; Tsai P; Jefferis CA; Gupta R; Linehan WM; Alley M; Bates SE
Clin Cancer Res; 2001 Mar; 7(3):620-33. PubMed ID: 11297258
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and biological evaluation of 11-substituted 6-aminobenzo[c]phenanthridine derivatives, a new class of antitumor agents.
Kock I; Heber D; Weide M; Wolschendorf U; Clement B
J Med Chem; 2005 Apr; 48(8):2772-7. PubMed ID: 15828815
[TBL] [Abstract][Full Text] [Related]
13. Update on NCI in vitro drug screen utilities.
Holbeck SL
Eur J Cancer; 2004 Apr; 40(6):785-93. PubMed ID: 15120034
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of imidazothioxanthones in murine and human tumor models in vitro and in vivo.
Varvaresou A; Iakovou K; Gikas E; Fichtner I; Fiebig HH; Kelland LR; Double JA; Bibby MC; Hendriks HR
Anticancer Res; 2004; 24(2B):907-19. PubMed ID: 15161044
[TBL] [Abstract][Full Text] [Related]
15. Application of a human tumor colony-forming assay to new drug screening.
Shoemaker RH; Wolpert-DeFilippes MK; Kern DH; Lieber MM; Makuch RW; Melnick NR; Miller WT; Salmon SE; Simon RM; Venditti JM
Cancer Res; 1985 May; 45(5):2145-53. PubMed ID: 3986767
[TBL] [Abstract][Full Text] [Related]
16. Anticancer activity of natural cytokinins: a structure-activity relationship study.
Voller J; Zatloukal M; Lenobel R; Dolezal K; Béres T; Krystof V; Spíchal L; Niemann P; Dzubák P; Hajdúch M; Strnad M
Phytochemistry; 2010 Aug; 71(11-12):1350-9. PubMed ID: 20553699
[TBL] [Abstract][Full Text] [Related]
17. Web-based tools for mining the NCI databases for anticancer drug discovery.
Fang X; Shao L; Zhang H; Wang S
J Chem Inf Comput Sci; 2004; 44(1):249-57. PubMed ID: 14741034
[TBL] [Abstract][Full Text] [Related]
18. Development of a panel of 15 human ovarian cancer xenografts for drug screening and determination of the role of the glutathione detoxification system.
Kolfschoten GM; Pinedo HM; Scheffer PG; Schlüper HM; Erkelens CA; Boven E
Gynecol Oncol; 2000 Mar; 76(3):362-8. PubMed ID: 10684711
[TBL] [Abstract][Full Text] [Related]
19. The preclinical new drug research program of the National Cancer Institute.
Driscoll JS
Cancer Treat Rep; 1984 Jan; 68(1):63-76. PubMed ID: 6692438
[TBL] [Abstract][Full Text] [Related]
20. Double blockade of cell cycle at g(1)-s transition and m phase by 3-iodoacetamido benzoyl ethyl ester, a new type of tubulin ligand.
Jiang JD; Denner L; Ling YH; Li JN; Davis A; Wang Y; Li Y; Roboz J; Wang LG; Perez-Soler R; Marcelli M; Bekesi G; Holland JF
Cancer Res; 2002 Nov; 62(21):6080-8. PubMed ID: 12414632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
